In a study presented at the 2012 annual meeting of the American Society of Radiation Oncology, researchers found that men with organ-confined prostate cancer can be treated successfully with stereotactic body radiation therapy. The five-year, multi-center study evaluated low-risk, intermediate-risk and high-risk patients for up to four years following treatment. At the five-year mark, the relapse-free survival rate was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients.
Men with organ-confined prostate cancer can be treated with focused stereotactic body radiotherapy (SBRT) in as few as five outpatient treatments, saving them time and money. To read more about the study, click here.
Austin CyberKnife accepts most insurance coverage as well as Medicare.
Additional prostate cancer news from around the web:
A recent study published by the Cancer Institute of New Jersey found that the definition of low-risk prostate cancer should not be the same for African American and Caucasian men. Read more.
The Wall Street Journal reports the results of a survey showing that the majority of people who receive cancer diagnoses choose to continue working after diagnosis and during treatment. Read more.
The New York Times reports that a new prostate cancer test could help supplement PSA testing to reduce false alarms and help determine more definitive diagnoses. Read more.